•
Sep 30, 2024

ClearPoint Neuro Q3 2024 Earnings Report

Achieved record revenue and growth of 41% and operational cash burn was reduced to $1.2 million.

Key Takeaways

ClearPoint Neuro reported a record revenue quarter with $8.1 million, a 41% year-over-year increase. The company's growth was fueled by new product introductions, adoption of the PRISM laser therapy system, and expansion of pre-clinical capabilities. Operational cash burn was reduced, and the company reaffirmed its full year 2024 revenue outlook of between $30.0 and $33.0 million.

Reported quarterly revenue of $8.1 million, a 41% year-over-year increase.

Navigation and device revenue was $2.9 million, a 49% year-over-year increase.

Overall product revenue, including biologics and drug delivery, grew 127% to $5.5 million.

Quarterly operational cash burn reduced to $1.2 million, a 33% year-over-year decrease.

Total Revenue
$8.12M
Previous year: $5.76M
+41.0%
EPS
-$0.18
Previous year: -$0.2
-10.0%
Gross Profit
$4.85M
Previous year: $3.27M
+48.1%
Cash and Equivalents
$21.6M
Previous year: $24.3M
-11.3%
Free Cash Flow
-$1.21M
Previous year: -$1.77M
-31.6%
Total Assets
$40.2M
Previous year: $43.8M
-8.3%

ClearPoint Neuro

ClearPoint Neuro

ClearPoint Neuro Revenue by Segment

Forward Guidance

The Company reaffirms its full year 2024 revenue outlook of between $30.0 and $33.0 million.